- Name: Cai Ling
- Title: Chief physician
- Email:
- Phone:
Oct 2011 - present
SYSUCC, Guangzhou, China
Department of Radiation Oncology, Associate professor
Specializes in thoracic cancer treatment and research
Oct 2008 – Oct 2011
Centre Hospitalier Universitairevaudois, Chuv
Lausanne, Switzerland
Department of Radiation Oncology, Clinical Fellow
- Worked as fellow-ship and participated in clinical works
- Conducted clinical research on primary bone lymphoma (multi-center research in
USA, Swiss, China, France, Spain, Netherlands, and Greece) for Rare Cancer
Network and the outcome comparison of pre-operation radiotherapy vs.
post-operation radiotherapy in sarcoma
- Received the training of Image-Guided Radiotherapy and gained more
experience in the treatment of prostate cancer, sarcoma and breast cancer
- Completed the M.D thesis on primary bone lymphoma
Jul 2005 – Oct 2008
SYSUCC Guangzhou, China
Department of Radiation Oncology, Attending Radiation Oncologist
- Attended a three-year specialty training program for Radiation Oncology
- Took charge of the diagnosis and treatment of 15 hospital beds
- Administered the treatment project including the design of irradiation
beams, the qualitative during the period of treatment
- Received the training of traditional irradiation or the 3-dimensional conformal
radiotherapy according to the tumor image from CT or MRI scan
- Treated the complication during the full cycle of treatment
- Specialized in esophageal cancer; lung cancer; breast cancer and liver cancer,
lymphoma, colorectal cancer, prostate cancer, et al.
- Attended the training for GCP and awarded the certification; participated in
several clinical trials for designed protocol
Sep 2002 - June 2005
SYSUCC Guangzhou, China
Department of Radiation Oncology, Resident physician
- Worked as medical assistant
- Completed the educational courses of medical oncology including Medical
Statistics, Advanced Pathology, Clinical Oncology and Design of Scientific Research,
et al
- Completed the phase I and II study of CMNa (one kind of radio sensitizer)
combined with concurrent radio chemotherapy for advanced esophageal carcinoma
- Awarded the diploma in medical oncology
Jun 1998 - Aug 2002
The Eighth Municipal Hospital, Guangzhou, China
Department of Oncology, Resident in cancer medicine with specialized in radiation
oncology
- Conducted the primary diagnosis and treatment of various tumor types
- Implemented the chemotherapy and radiotherapy
- Participated in the radiosensitive therapy for nasopharyngeal carcinoma
Jul 1992 – Jul 1998
The Eighth Municipal Hospital, Guangzhou, China
Department of Internal Medicine, Resident
- Conducted the diagnosis and clinical therapy of patients specialized in infectious disease
Sep 1986- Jul 1992
Sun Yat-sen University of MedicalSciences, Guangzhou, China
Diploma in Medicine, Bachelor Degree, July 1992
Sep 2002- Jun 2005
Sun Yat-sen University , Cancer Center,Guangzhou, China
Diplomain Medical Oncology, Master Degree, June 2005
Mar 2009- Oct 2011
University of Lausanne, Lausanne, Switzerland
Doctoral Degree in Medicine, February,2012
1. Cai L, Zhu JF, Zhang XW, Lin SX, Su XD, Lin P, Chen K, Zhang LJ. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neurooncol. 2014 Nov;120(2):423-30.
2. Zhu JF1, Feng XY2, Zhang XW3, Wen YS4, Lin P4, Rong TH4, Cai L5, Zhang LJ.Time-varying pattern of postoperative recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung cancer (NSCLC): results of a single-center study of 994 Chinese patients. PLoS One. 2014 Sep 9;9(9):e106668.
3. Zhu JF, Cai L, Yang HX, et al. Echinoderm microtubule-associated protein-like-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexistingin Chinese patients with lung adenocarcinoma. Thoracic Cancer. Accepted, 2014.
4. Zhu JF, Cai L, Zhang XW, et al. High plasma fibrinogen concentration and platelet count unfavorably impact survival in non-small cell lung cancer patients with brain metastases. Chin J Cancer; 2014; Vol. 33 Issue 2: 96-104.
5. Cai L, Mirimanoff RO, Mouhsine E, et al. Prognostic factors in adult soft tissue sarcoma treated with surgery combined with radiotherapy: a retrospective single-center study on 164 patients. Rare Tumors. 2013; Volume 5:e55
6. Cai L, Stauder MC, Zhang YJ, Poortmans P, Li YX, Constantinou N, Thariat J, Kadish SP, Nguyen TD, Kirova YM, Ghadjar P, Weber DC, Bertran VT, Ozsahin M, Mirimanoff RO .Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):284-91. Epub 2011 Nov 11
7. Zhang LJ, Cai L, Li Z, Wang WP, Guo K, Shao JY, Wang JY, Yu H, Rong TH. Relationship between epidermal gowth factor receptor gene mutation and gene copy number in Chinese patients with non-small cell lung cancer. Chin J Cancer. 2012 May 8. doi: 10.5732/cjc.011.10409.
8. Guo K, Cai L, Zhang Y, Zhu JF, Rong TH, Lin P, Hao CL, Wang WP, Li Z, Zhang LJ. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chin J Cancer. 2012 Aug;31(8):399-408. doi: 10.5732/cjc.011.10406. Epub 2012 May 8.
9. Liang SX, Huang XB, Zhu XD, Zhang WD, Cai L, Huang HZ, Li YF, Chen L, Liu MZ. Dosimetric predictor identification for radiation-induced liver disease after hypofractionated conformal radiotherapy for primary liver carcinoma patients with Child-Pugh Grade A cirrhosis. Radiother Oncol. 2011 Feb;98(2):265-9. Epub 2010Nov 4.
10. Xi M, Liu MZ, Wang HX, Cai L, Zhang L, Xie CF, Li QQ. Radiation induced sarcoma in patients with nasopharyngeal carcinoma. Cancer. 2010 Dec 1;116(23):5479-86. doi: 10.1002/cncr.25329. Epub 2010 Aug 16
11. M. Xi, M.Z. Liu, Q.Q. Li, L.Cai, L.Zhang, Y.H. Hu. Analysis of abdominal organ motion using four-dimensional CT. Chinese Journal of Cancer. 2009, 28:989-93.
12. Cai L., Liu M.Z, Wang X.S., et al. Radiotherapy combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma – a prospective clinical trial. Chinese-German Journal of Clinical Oncology, 2008, Vol.7, No.2, P64-68
13. J .Yang, M.Z. Liu, L. Cai, Y.H. Hu, H. Liu, Q.Q. Li, N.J. Cui. Phase = 2 \* ROMAN II clinical trial of sodium glyci-didazole (CM-Na) combined with concurrent radiochemotherapy for advanced esophageal carcinoma. Aizheng. 2008, 27: 622-6.
14. M. Xi, M.Z. Liu, X.W. Deng, L. Zhang, X. Y. Wang, H. Liu, Q.Q. Li, Y.H. Hu, L. Cai, N.J. Cui. Define internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiotherapy & Oncology. 2007, 84: 272-8.
15. E.C. Chen, M.Z. Liu, Y.H. Hu, L. Cai, Q.Q. LI, H. Liu. A case-control study on unresectable esophageal carcinoma patients with radiochemotherapy or radiotherapy. Chin J Radiat Oncol. 2007, 16: 416-19.
16. X.S. Wang, M.Z. Liu, C.Q. Zhang, L. Cai, N.J. Cui. Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squarmous cell carcinoma patients- A report of 43 cases. Chinese journal of Cancer. 2006, 25: 1428-32
17. Cai L.;. Liu M.Z;. Gu M.F, et al. Phase = 1 \* ROMAN I Study of CM-Na Combined Concurrent Radiochemotherapy for Advanced Esophageal Carcinoma. Chinese Journal of Cancer. 2005, vol24, N05:582-586
18. Liu M.Z, Cai L.. Primary Liver cancer. Principle and practice of radiation oncology (First Edition). Sun Yat-sen University Publishers, 2005.
19. E.C. Chen, M.Z. Liu, Y.H. Hu, Q.Q. Li, H. Liu, L. Cai, H.X. Lin, Y. Huang, H.Y. Wang, N.J. Cui. Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy. Chinese Journal of Cancer. 2005,24: 731-34.
20. M.Z. Liu, X.S. Wang, L. Cai, et al. Treatment and Prognostic Factors in 74 Patients with Dermatofibrosarcoma Protuberans. Chinese Journal of Oncology.2005, vol 27.No2:122-125
21. E.C. Cheng, L. Cai, M. Z. Liu. The progress of extra-radiotherapy in liver cancer. Foreign Medical Sciences (Oncology Section). May 2004, vol.31, No 5:374-378.
Updated by International Office, Sun Yat-sen University Cancer Center